Japan's Ministry of Health has approved Sanofi's Wayrilz (rilzabrutinib), a novel oral BTK inhibitor, for treating persistent or chronic immune thrombocytopenia (ITP) in patients unresponsive or intolerant to other treatments. The approval is based on the LUNA 3 phase 3 study, which showed Wayrilz significantly improved platelet counts and quality of life compared to placebo. This drug addresses the root causes of ITP by modulating multiple immune pathways and is already approved in the US, EU, UAE, and UK. Sanofi is also investigating Wayrilz for other rare immune diseases, highlighting its potential beyond ITP.
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Research & Development Pharma, effective September 1, 2026. Fontoura brings over 25 years of experience in medicine and pharmaceutical innovation, having held seni...
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
Japan's Ministry of Health has approved Sanofi's Sarclisa subcutaneous (SC) formulation for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval is based on the IRAKLIA phase 3 study showing the SC form is...
